EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
Further increase in expected orders for PrimeStore MTM sample collection devices Orders received for the two months ending July totalling $9.4m
EKF Diagnostics Holdings plc announces that it has issued and allotted 500,000 ordinary shares of one pence each in the share capital of the Company following an exercise of options on 5 May 2020.
EKF Diagnostics Holdings plc confirms that the Annual Report and Accounts for the year ended 31 December 2019
EKF Diagnostics Holdings plc announces that it has signed a three-year distribution agreement with Tosoh Europe N.V.
EKF Diagnostics Holdings plc announces that it has signed an agreement with Source BioScience UK Ltd
EKF Diagnostics Holdings plc announces that further to yesterday’s announcement regarding the significant increase in manufacturing demand for the PrimeStore MTM sample collection device
EKF Diagnostics Holdings plc provides an update on the significant increase in manufacturing demand from Longhorn Vaccines and Diagnostics LLC in the US.
EKF Diagnostics Holdings plc announces its final results for the year ended 31 December 2019.
EKF Diagnostics Holdings plc provides shareholders with an update on current trading in light of the COVID-19 pandemic